These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 11282910)
1. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910 [TBL] [Abstract][Full Text] [Related]
2. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802 [TBL] [Abstract][Full Text] [Related]
3. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207 [TBL] [Abstract][Full Text] [Related]
4. Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Llaverías G; Laguna JC; Alegret M Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916 [TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225 [TBL] [Abstract][Full Text] [Related]
6. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Tardif JC; Grégoire J; L'Allier PL; Anderson TJ; Bertrand O; Reeves F; Title LM; Alfonso F; Schampaert E; Hassan A; McLain R; Pressler ML; Ibrahim R; Lespérance J; Blue J; Heinonen T; Rodés-Cabau J; Circulation; 2004 Nov; 110(21):3372-7. PubMed ID: 15533865 [TBL] [Abstract][Full Text] [Related]
7. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Bocan TM; Krause BR; Rosebury WS; Lu X; Dagle C; Bak Mueller S; Auerbach B; Sliskovic DR Atherosclerosis; 2001 Jul; 157(1):97-105. PubMed ID: 11427208 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217 [TBL] [Abstract][Full Text] [Related]
9. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat. Post SM; Zoeteweij JP; Bos MH; de Wit EC; Havinga R; Kuipers F; Princen HM Hepatology; 1999 Aug; 30(2):491-500. PubMed ID: 10421659 [TBL] [Abstract][Full Text] [Related]
10. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609 [TBL] [Abstract][Full Text] [Related]
11. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages. Rodriguez A; Usher DC Atherosclerosis; 2002 Mar; 161(1):45-54. PubMed ID: 11882316 [TBL] [Abstract][Full Text] [Related]
12. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice. Terasaka N; Miyazaki A; Kasanuki N; Ito K; Ubukata N; Koieyama T; Kitayama K; Tanimoto T; Maeda N; Inaba T Atherosclerosis; 2007 Feb; 190(2):239-47. PubMed ID: 16626720 [TBL] [Abstract][Full Text] [Related]
13. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727 [TBL] [Abstract][Full Text] [Related]
14. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Nicolosi RJ; Wilson TA; Krause BR Atherosclerosis; 1998 Mar; 137(1):77-85. PubMed ID: 9568739 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Insull W; Koren M; Davignon J; Sprecher D; Schrott H; Keilson LM; Brown AS; Dujovne CA; Davidson MH; McLain R; Heinonen T Atherosclerosis; 2001 Jul; 157(1):137-44. PubMed ID: 11427213 [TBL] [Abstract][Full Text] [Related]
17. Inhibitors of acyl-coenzyme a: cholesterol acyltransferase. Miyazaki A; Kanome T; Watanabe T Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):463-9. PubMed ID: 16503866 [TBL] [Abstract][Full Text] [Related]
18. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Raal FJ; Marais AD; Klepack E; Lovalvo J; McLain R; Heinonen T Atherosclerosis; 2003 Dec; 171(2):273-9. PubMed ID: 14644397 [TBL] [Abstract][Full Text] [Related]
19. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. Delsing DJ; Jukema JW; van de Wiel MA; Emeis JJ; van der Laarse A; Havekes LM; Princen HM J Cardiovasc Pharmacol; 2003 Jul; 42(1):63-70. PubMed ID: 12827028 [TBL] [Abstract][Full Text] [Related]
20. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles. Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]